相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Peter M. Voorhees et al.
BLOOD (2020)
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
Marion Eveillard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients
Sanjay Kumar et al.
LEUKEMIA (2019)
MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins
Lauren M. Moore et al.
CLINICA CHIMICA ACTA (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry
Lusia Sepiashvili et al.
CLINICAL CHEMISTRY (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study
Ola Landgren et al.
BLOOD (2019)
Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay
Katie L. Thoren et al.
JOURNAL OF APPLIED LABORATORY MEDICINE (2019)
A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference
John R. Mills et al.
BLOOD (2018)
Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences
Christopher R. McCudden et al.
CLINICAL BIOCHEMISTRY (2018)
Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies
Marina Zajec et al.
JOURNAL OF PROTEOME RESEARCH (2018)
Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease
Katie L. Thoren
SEMINARS IN HEMATOLOGY (2018)
MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms
Taxiarchis Kourelis et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody Therapies
John R. Mills et al.
JOURNAL OF APPLIED LABORATORY MEDICINE (2017)
The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic
Paolo Milani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration
H. Robert Bergen et al.
CLINICAL CHEMISTRY (2016)
Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry
John R. Mills et al.
CLINICAL CHEMISTRY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Detecting monoclonal immunoglobulins in human serum using mass spectrometry
John R. Mills et al.
METHODS (2015)
Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy
David R. Barnidge et al.
JOURNAL OF PROTEOME RESEARCH (2014)
分享论文
